LumiraDx Investor Presentation Deck

We Have Launched a Broad Menu of Tests with Lab Comparable Performance TAM¹ Market² TAM¹ Market² LORE SARS-COM-2 Ag SARS-CoV-2 Ag Test US/EU/JP/BR Lump INR INR Test lumiraDx™ $500M SARS-CoV-2 Ab EU SARS-CoV-2 Ab Test Coagulation Luminox POOL TEST SARS-CoV-2 Ag Pool Test D-Dimer SARS-CoV2 Ag $12B D-Dimer Test $700M EU MORS SARS-CoV-2 Ag Ultra Ti SARS-CoV-2 Ag Ultra Test EU CRP Test POOL TEST Inflammation $300M EU SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra Pool Test Respiratory HbAlc SARS-COM-2 & Flu A/B SARS-CoV-2 & Flu A/B Test $1.5-3B ummo EU / JP Diabetes HbAlc Test $1.3B EU de SARS-COV 2 & RSV SARS-CoV-2 & RSV Test $200-400M EU Cardiovascular ma NT-proBNP Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. NT-proBNP Test $350M EU amira COVID-19 Self-Tast mies apes 2 years I Suminox -- $9B ☐☐☐☐ EU SO TESTS lumiaDx SAS-COV RNA STAR Area Legend d 8.3 Enzyme Molecular $12B/$12B/$1B RNA STAR COVID RNA STAR COVID RNA STAR Complete COVID & Flu RNA STAR Complete Qualitative Immunoassay US / EU Quantitative Immunoassay (1) 2021 Global Total Addressable Market ("TAM"), based on our assumptions, including the (a) existing market sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. COVID TAMs difficult to estimate at present, may overlap with each other. (2) Markets with regulatory authorization. Commercial launch of Amira on hold. 13

View entire presentation